Back to Directory
BASE Rx
Cambridge
Founded 2025
Genome-editing platform mapping cancer drug resistance and druggable vulnerabilities
BASE Rx is a Wellcome Sanger Institute spin-out applying genome-editing and DNA sequencing technologies to cancer drug discovery.
The company maps single-base genetic variants to identify druggable vulnerabilities in cancer genes and predict the DNA changes that drive resistance to cancer therapies.
BASE Rx aims to help pharmaceutical and biotechnology partners identify cancer treatments less likely to fail due to acquired drug resistance.